Lung cancer: First-in-man phase I trial with lorlatinib

被引：1
|
作者：
Romero D.
机构：
来源：
Nature Reviews Clinical Oncology | 2018年 / 15卷 / 1期
关键词：
D O I：
10.1038/nrclinonc.2017.201
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：7 / 7
相关论文
共 50 条
  • [1] Calcium Electroporation for Keloids: A First-in-Man Phase I Study
    Falk, Hanne
    Vissing, Mille
    Wooler, Gitte
    Gehl, Julie
    DERMATOLOGY, 2021, 237 (06) : 961 - 969
  • [2] Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
    Shaw, Alice T.
    Felip, Enriqueta
    Bauer, Todd M.
    Besse, Benjamin
    Navarro, Alejandro
    Postel-Vinay, Sophie
    Gainor, Justin F.
    Johnson, Melissa
    Dietrich, Jorg
    James, Leonard P.
    Clancy, Jill S.
    Chen, Joseph
    Martini, Jean-Francois
    Abbattista, Antonello
    Solomon, Benjamin J.
    LANCET ONCOLOGY, 2017, 18 (12): : 1590 - 1599
  • [3] First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors
    Falchook, Gerald S.
    Kurzrock, Razelle
    Amin, Hesham M.
    Xiong, Wenyuan
    Fu, Siqing
    Piha-Paul, Sarina A.
    Janku, Filip
    Eskandari, Ghazaleh
    Catenacci, Daniel V.
    Klevesath, Manfred
    Bruns, Rolf
    Stammberger, Uz
    Johne, Andreas
    Bladt, Friedhelm
    Friese-Hamim, Manja
    Girard, Pascal
    El Bawab, Samer
    Hong, David S.
    CLINICAL CANCER RESEARCH, 2020, 26 (06) : 1237 - 1246
  • [4] The RAISE Trial: A Novel Device and First-in-Man Trial
    Sun, Wei
    Zou, Huayiyang
    Yong, Yonghong
    Liu, Boxun
    Zhang, Hao
    Lu, Jieyu
    Shen, Yihui
    Li, Peng
    Xu, Tianhua
    Chen, Xuguan
    Du, Anning
    Jiang, Ming
    Hua, Yang
    Sheng, Yanhui
    Zhou, Bin
    Lotan, Chaim
    Kong, Xiangqing
    CIRCULATION-HEART FAILURE, 2022, 15 (04) : 346 - 356
  • [5] HepaVac-101 first-in-man therapeutic cancer vaccine phase I/II clinical trial for hepatocellular carcinoma patients.
    Buonaguro, Luigi
    Mayer-Mokler, Andrea
    Accolla, Roberto
    Ma, Yuk Ting
    Heidenreich, Regina
    Avallone, Antonio
    Simeone, Ester
    Koenigsrainer, Alfred
    Loeffler, Markus
    Gouttefangeas, Cecile
    Flohr, Christian
    Ludwig, Joerg
    Rammensee, Hans-Georg
    Inarrairaegui, Mercedes
    Francque, Sven
    Chaumette, Tanguy
    Weinschenk, Toni
    Reinhardt, Carsten
    Gnad-Vogt, Senta Ulrike
    Singh, Harpreet
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Coronary Stenting with MGuard: First-In-Man Trial
    Kaluski, Edo
    Hauptmann, Karl Eugen
    Mueller, Ralf
    Tsai, Steve
    Klapholz, Marc
    Grube, Eberhard
    JOURNAL OF INVASIVE CARDIOLOGY, 2008, 20 (10): : 511 - 515
  • [7] First-in-man Phase I trial of BYK408740, an oral histone deacetylase inhibitor, in patients with advanced malignancies
    Ang, J. E.
    Hauns, B.
    Mais, A.
    Parker, A.
    Lal, R.
    Olmos, D.
    Mollenhauer, M.
    Walz, A.
    de Bono, J. S.
    EJC SUPPLEMENTS, 2008, 6 (12): : 123 - 124
  • [8] A first-in-man phase 1 trial for long-acting TransCon Growth Hormone
    Gilfoyle, David
    Mortensen, Eva
    Christoffersen, Eva Dam
    Leff, Jonathan A.
    Beckert, Michael
    GROWTH HORMONE & IGF RESEARCH, 2018, 39 : 34 - 39
  • [9] Irreversible Electroporation of Renal Cell Carcinoma: A First-in-Man Phase I Clinical Study
    Maciej Pech
    Andreas Janitzky
    Johann Jacob Wendler
    Christof Strang
    Simon Blaschke
    Oliver Dudeck
    Jens Ricke
    Uwe-Bernd Liehr
    CardioVascular and Interventional Radiology, 2011, 34 : 132 - 138
  • [10] Irreversible Electroporation of Renal Cell Carcinoma: A First-in-Man Phase I Clinical Study
    Pech, Maciej
    Janitzky, Andreas
    Wendler, Johann Jacob
    Strang, Christof
    Blaschke, Simon
    Dudeck, Oliver
    Ricke, Jens
    Liehr, Uwe-Bernd
    CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY, 2011, 34 (01) : 132 - 138
12345